According to @StockMarketNerd, Hims & Hers Health (HIMS) has executed well and overcome several real risks, a performance the source says deserves credit (source: @StockMarketNerd on X, Oct 16, 2025). Per the same source, the CEO should not engage with short-squeeze posts, and doing so while additional share sales are imminent is especially problematic, raising timing and potential dilution concerns for traders (source: @StockMarketNerd on X, Oct 16, 2025). The source did not address any crypto market implications (source: @StockMarketNerd on X, Oct 16, 2025).